Risk of multiple primary malignancies following treatment of Hodgkin lymphoma

Blood

Volumn 124, Issue 3, 2014, Pages 319-327

  Van Eggermond, Anna M ^a   Schaapveld, Michael ^a,b   Lugtenburg, Pieternella J ^c   Krol, Augustinus D G ^d   De Boer, Jan Paul ^a   Zijlstra, Josée M ^e   Raemaekers, John M M ^f   Kremer, Leontien C M ^g   Roesink, Judith M ^h   Louwman, Marieke W J ⁱ   Aleman, Berthe M P ^a   Van Leeuwen, Flora E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Centre the Netherlands   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g EMMA CHILDREN S HOSPITAL   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ The Netherlands   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CAUSE OF DEATH; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SECOND CANCER; UROGENITAL TRACT CANCER;

ADULT; AGE FACTORS; COHORT STUDIES; EDUCATION, MEDICAL, CONTINUING; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NETHERLANDS; RISK FACTORS; YOUNG ADULT;

EID: 84904515663     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-532184     Document Type: Article

References (45)

1. Integraal Kankercentrum Nederland. Comprehensive Cancer Centre The Netherlands. Dutch cancer figures. http://cijfersoverkanker.nl/selecties/ Dataset-2/img511e01347d788. Accessed June 29, 2012.
2. Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol. 2012;9(8):450-459.
3. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20(16):3484-3494.
4. Hodgson DC, Gilbert ES, Dores GM, et al. Longterm solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25(12):1489-1497. (Pubitemid 46759253)
5. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100(6):1989-1996. (Pubitemid 35001228)
6. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18(3):498-509. (Pubitemid 30078531)
7. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18(3):487-497. (Pubitemid 30078530)
8. Abramson DH, Melson MR, Dunkel IJ, Frank CM. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology. 2001;108(10):1868-1876. (Pubitemid 32905948)
9. Armstrong GT, Liu W, Leisenring W, et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2011;29(22):3056-3064.
10. Bhatia S, Yasui Y, Robison LL, et al Late Effects Study Group. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21(23):4386-4394. (Pubitemid 46621816)
11. Marees T, van Leeuwen FE, Schaapveld M, et al. Risk of third malignancies and death after a second malignancy in retinoblastoma survivors. Eur J Cancer. 2010;46(11):2052-2058.
12. Kwast AB, Liu L, Roukema JA, et al. Increased risks of third primary cancers of non-breast origin among women with bilateral breast cancer. Br J Cancer. 2012;107(3):549-555.
13. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21(18):3431-3439. (Pubitemid 46603515)
14. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878- 1886. (Pubitemid 46348183)
15. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994;12(2):312-325. (Pubitemid 24056405)
16. De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood. 2009;113(16):3679-3681.
17. Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29(1):19-24. (Pubitemid 46535194)
18. Schouten LJ, Höppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol. 1993;22(3):369-376. (Pubitemid 23208931)
19. Cancer incidence in five continents. Volume IX. IARC Sci Publ. 2008;(160):1-837.
20. Integraal Kankercentrum Nederland. Comprehensive Cancer Centre The Netherlands. Netherlands Cancer Registry. Dutch cancer figures. http://cijfersoverkanker.nl/. Accessed June 29, 2012.
21. Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol. 1988;6(2):239-252. (Pubitemid 18068598)
22. Eghbali H, Raemaekers J, Carde P; EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol Suppl. 2005;(66):135-140. (Pubitemid 40873991)
23. Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al European Organisation for Research and Treatment of Cancer. The achievements of the EORTC Lymphoma Group. Eur J Cancer. 2002;38(suppl 4):S107-S113. (Pubitemid 34169772)
24. Somers R, Tubiana M, Henry-Amar M. EORTC Lymphoma Cooperative Group studies in clinical stage I-II Hodgkin's disease 1963-1987. Recent Results Cancer Res. 1989;117:175-181.
25. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989;73(1):47-56. (Pubitemid 19040952)
26. Eindhoven Cancer Registry. Comprehensive Cancer Centre South 2012. http://www.iknlzuid.nl. Accessed December 15, 2010.
27. International Association of Cancer Registries. International rules for multiple primary cancers. January 7, 2004. http://www.iacr.com.fr. Accessed July 24, 2013.
28. Pearson ES, Hartley HO. Biometrika Tables for Statisticians. 3rd ed. London, United Kingdom: Biometrika Trust; 1976.
29. Breslow NE, Day NE. Statistical methods in cancer research. Volume II - The design and analysis of cohort studies. IARC Sci Publ. 1987;(82):1-406.
30. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
31. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
32. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290(4):465-475. (Pubitemid 37430500)
33. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003;95(13):971-980. (Pubitemid 36896714)
34. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94(3):182-192. (Pubitemid 34162752)
35. Henderson TO, Oeffinger KC, Whitton J, et al. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med. 2012;156(11):757-766, W-260.
36. Nottage K, McFarlane J, Krasin MJ, et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol. 2012;30(20):2552-2558.
37. van den Belt-Dusebout AW, Aleman BM, Besseling G, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys. 2009;75(5):1420-1429.
38. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074-1078.
39. Bittorf B, Kessler H, Merkel S, et al. Multiple primary malignancies: An epidemiological and pedigree analysis of 57 patients with at least three tumours. Eur J Surg Oncol. 2001;27(3):302-313. (Pubitemid 32621758)
40. Schaapveld M, Visser O, Louwman WJ, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110(1):189-197. (Pubitemid 351793865)
41. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med. 1990;322(1):7-13. (Pubitemid 20023826)
42. Morton LM, Dores GM, Curtis RE, et al. Stomach cancer risk after treatment for hodgkin lymphoma. J Clin Oncol. 2013;31(27):3369-3377.
43. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652.
44. Hodgson DC, Koh ES, Tran TH, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer. 2007;110(11):2576-2586. (Pubitemid 350174945)
45. Specht L, Yahalom J, Illidge T, et al; ILROG. Modern radiation therapy for hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2013.